CD274 and esophageal squamous cell carcinoma: This study stratified patients based on PD-L1 expression levels and found that, except for the Sintilimab group, advanced ESCC patients with PD-L1 ≥10% showed greater OS benefits compared to those without PD-L1 expression selection.